Related Experiment Video
Updated: Jan 9, 2026
Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
Published on: August 1, 2018
Disulfide-bonded YC18: A membrane-targeting peptide with superior efficacy against Staphylococcus aureus infections
Jinai Gao1, Yi Wang2, Wanting Wang3
1Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), State Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, Chinese Academy of Sciences, No. 17 Longxin Road, Kunming, Yunnan 650201, China; School of Molecular Medicine, Hangzhou Institute for Advanced Study, Hangzhou 310024, Zhejiang, China; Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Abstract:
The escalating crisis of antimicrobial resistance, particularly in Staphylococcus aureus (S. aureus) infections, demands innovative therapeutics beyond conventional antibiotics. Spider venom represents a rich source of bioactive peptides with untapped therapeutic potential. Here, we report YC18, a novel disulfide-stabilized β-hairpin peptide derived from the cDNA library of Chilobrachys liboensis (C. liboensis). This peptide exhibits potent and selective activity against S. aureus, with a minimum inhibitory concentration (MIC) of 6.25 μg/mL. Unlike vancomycin, YC18 exhibits low resistance development even after 35 serial passages of S. aureus, underscoring its clinical potential. Structural prediction revealed that YC18's unique dual-disulfide scaffold (Cys2-Cys15, Cys6-Cys11) confers exceptional stability and efficacy, as validated by peptide analog studies. Mechanistically, YC18 selectively targets phosphatidylglycerol (PG) to disrupt bacterial membranes, a process elucidated through molecular dynamics simulations. With high plasma stability, low cytotoxicity, and efficacy in murine infection models, YC18 emerges as a promising candidate for combating S. aureus infections.
